Form 4: Bicycle Therapeutics CTO Reports Equity Awards & Tax Sales

Bicycle Therapeutics' Chief Technology Officer, Michael Skynner, reported the acquisition of new equity awards and subsequent 'sell to cover' transactions for tax obligations.

Summary

• Michael Skynner, Chief Technology Officer of Bicycle Therapeutics PLC, acquired 50,000 restricted share units (RSUs) on January 2, 2026.
• These RSUs are scheduled to vest one-fourth (1/4) on January 2, 2027, with the remaining RSUs vesting in 12 equal quarterly installments thereafter.
• Skynner also acquired 100,000 employee stock options on January 2, 2026, with an exercise price of $7.08 per share.
• These options will vest one-fourth (1/4) on January 2, 2027, and the remaining shares in 36 equal monthly installments thereafter, expiring on January 2, 2036.
• To cover statutory tax withholding obligations related to RSU vesting, Skynner sold 3,045 ordinary shares at a weighted average price of $6.8 on January 2, 2026.
• An additional 3,266 ordinary shares were sold at a weighted average price of $6.46 on January 5, 2026, for the same tax withholding purpose.
• Following these reported transactions, Skynner beneficially owns 161,966 ordinary shares and 100,000 employee stock options.

Sentiment

Score: 7

Explanation: The filing reflects standard executive compensation practices, including significant equity grants, which are generally positive for aligning management incentives. The share sales are non-discretionary for tax purposes, mitigating any negative interpretation.

Positives

• Grant of 50,000 Restricted Share Units (RSUs) to the CTO, aligning management incentives with long-term shareholder value.
• Grant of 100,000 Employee Stock Options to the CTO, further incentivizing long-term performance and company growth.

Negatives

• Sales of 6,311 shares (3,045 and 3,266) by the CTO, although for tax purposes, represent a reduction in direct shareholding.

Future Outlook

The vesting schedules for the granted Restricted Share Units and Employee Stock Options extend into 2027 and beyond, indicating a long-term incentive structure for the Chief Technology Officer.

Management Comments

• The sale of shares was mandated by the Reporting Person's award agreement, requiring the satisfaction of minimum statutory tax withholding obligations to be funded by a 'sell to cover' transaction, and does not represent a discretionary sale by the Reporting Person.

Industry Context

The grant of equity awards (RSUs and stock options) and subsequent 'sell to cover' transactions for tax purposes are standard practices in executive compensation within the biotechnology and pharmaceutical industries. These mechanisms are designed to align executive interests with long-term company performance while managing tax liabilities associated with equity vesting.

Comparison to Industry Standards

• Equity grants, such as Restricted Share Units and stock options, are a common component of executive compensation packages across the biotechnology sector, similar to practices observed at companies like Moderna or BioNTech, aiming to incentivize long-term value creation.
• The 'sell to cover' mechanism for statutory tax withholding is a widely accepted and standard practice for executives receiving equity compensation, ensuring compliance with tax obligations upon vesting, consistent with practices at many publicly traded companies.

Stakeholder Impact

• Shareholders: The equity grants to the CTO enhance the alignment of management's interests with long-term shareholder value. The 'sell to cover' transactions are routine and do not indicate a discretionary sale.
• Employees: The executive compensation structure, including equity awards, may set a precedent or benchmark for other senior employees within the company.

Next Steps

• Continued vesting of 50,000 RSUs, with one-fourth vesting on January 2, 2027, and the remainder in 12 equal quarterly installments.
• Continued vesting of 100,000 employee stock options, with one-fourth vesting on January 2, 2027, and the remainder in 36 equal monthly installments.

Key Dates

Recommendation

This Form 4 details routine executive compensation and tax-related share sales. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The grants align executive incentives, which is a neutral to slightly positive factor, but the sales are non-discretionary.

Keywords

Bicycle Therapeutics, BCYC, Michael Skynner, CTO, Form 4, RSU, stock options, equity compensation, insider transaction, sell to cover, beneficial ownership